1. Akadeemia tee 21 Tallinn 12680 Estonia www.inbio.ee e-mail: info@inbio.ee Reg.nr.:10565826 InBio Ltd. ANTIBODIES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS

2. Akadeemia tee 21 Tallinn 12680 Estonia www.inbio.ee e-mail: info@inbio.ee Reg.nr.:10565826 Facts on InBio Established in Tallinn, 1999 General business idea: to develop new effective and selective skin cancer therapeutics and diagnostics. The company was initiated by a group of scientists of National Institute of Chemical Physics and Biophysics and Karolinska Institute, Sweden

3. Akadeemia tee 21 Tallinn 12680 Estonia www.inbio.ee e-mail: info@inbio.ee Reg.nr.:10565826 199920002001 Turnover10000225000190000 Profit before taxes -2000190008000 Equity3300 Employees247 Financial results (EUR):

4. Akadeemia tee 21 Tallinn 12680 Estonia www.inbio.ee e-mail: info@inbio.ee Reg.nr.:10565826 Background for product development Cancer is the second most common cause of death in the developed world The limits of usefulness are being approached for conventional therapies and further advances will require principally new approaches The foreseen products of our company are prototypes of new anti-cancer drugs that are characterised by: –-high degree of selectivity –-efficient delivery

5. Akadeemia tee 21 Tallinn 12680 Estonia www.inbio.ee e-mail: info@inbio.ee Reg.nr.:10565826 What is antibody? Antibodies are made by a class of white blood cells They are naturally present in the blood Biological function is to perform defence functions Each antigen causes the formation of a specific antibody Recombinant DNA technology allows the engineer antibodies It is possible to produce complete antibodies in cell culture systems.

6. Akadeemia tee 21 Tallinn 12680 Estonia www.inbio.ee e-mail: info@inbio.ee Reg.nr.:10565826 Reasons to use antibodies in drug development Can be rationally designed and easily made Can be engineered to add fragmenmts that enhance their therapeutic potential Have no intrinsic toxicity as based on the natural molecules Monoclonal antibodies (mAbs)will not fail at the drug safety testing (phase I clinical trial stages) Technology is now advanced enough for therapeutic applications of mAbs

7. Akadeemia tee 21 Tallinn 12680 Estonia www.inbio.ee e-mail: info@inbio.ee Reg.nr.:10565826 What is new in our technology? Our technology combines two different platforms: Monoclonal antibodies against cancer-specific antigens –Modification of antibody sequence to make these mAbs membrane permeable Such approach helps to utilise intracellular cancer- specific targets that can not be usually reached Focus on skin cancer, first targets are GLI proteins

8. Akadeemia tee 21 Tallinn 12680 Estonia www.inbio.ee e-mail: info@inbio.ee Reg.nr.:10565826 What are GLI proteins? GLI proteins are gene switches GLI proteins are involved in development and lead cells to divide Abnormal activation of GLI proteins lead to cancer GLI proteins represent an attractive target for anticancer drug development

9. Akadeemia tee 21 Tallinn 12680 Estonia www.inbio.ee e-mail: info@inbio.ee Reg.nr.:10565826 Gene switch turned on Cancer develops Cancer development inhibited

10. Akadeemia tee 21 Tallinn 12680 Estonia www.inbio.ee e-mail: info@inbio.ee Reg.nr.:10565826 Cell penetrating peptides (CPPs) Family of peptides capable to penetrate cellular membranes We can transport the following molecules into cells using CPP technology: -other peptides -nucleic acids -proteins e.g. antibodies

11. Akadeemia tee 21 Tallinn 12680 Estonia www.inbio.ee e-mail: info@inbio.ee Reg.nr.:10565826 World antibody market: Currently more than 200 monoclonal antibodies are in development Targeted disorders include cancer, heart disease, infectious diseases and autoimmune diseases Market is still in its inception stage, Market size estimated at nearly $2.8 billion in 1999,

12. Akadeemia tee 21 Tallinn 12680 Estonia www.inbio.ee e-mail: info@inbio.ee Reg.nr.:10565826 World antibody market: Market forecast growth to almost $9.8 billion in 2004. Expected therapeutic antibody average annual growth rate is projected at 21,8% Diagnostic/therapeutic antibody AAGR will grow at fast nearly 50% rate Main Target Markets for InBio: Scandinavian Market U.S. market

13. Akadeemia tee 21 Tallinn 12680 Estonia www.inbio.ee e-mail: info@inbio.ee Reg.nr.:10565826 Timing and positioning Antibody based drugs are in the position of significant commercial growth InBio enters the market at the moment when all developers seek for new approaches InBio has new technology to make antibodies more effective InBio has involved outstanding specialists from all fields that are required to accomplish our business plan

14. Akadeemia tee 21 Tallinn 12680 Estonia www.inbio.ee e-mail: info@inbio.ee Reg.nr.:10565826 Benefits for the investor: Will invest in profitable business at evolving market Will invest in area that is significantly improving the well-being of the mankind Will get possession rights of a unique know- how and new technologies that will realise in new type of therapeutic and diagnostic tools